Revenio’s Interim report January-March 2026 to be published on April 28, 2026

Revenio will publish its Interim Report January-March 2026 on Tuesday, April 28, 2026, approximately at 09.00 a.m. (EEST). The report will be available at www.reveniogroup.fi/en/ after the publication.

An audiocast and teleconference call for analysts and investors will be held in English at 3.00 p.m. (EEST) on the same day.

The audiocast can be followed live at: https://revenio.events.inderes.com/q1-2026

To ask questions, please join the teleconference by registering using the following link: https://events.inderes.com/revenio/q1-2026/dial-in

After the registration, you will be provided with a phone number, user ID, and a conference ID to access the conference. To ask a question, please press #5 on your telephone keypad to enter the queue.

A recording of the audiocast will be published on www.reveniogroup.fi/en/ after the event.

For further information, please contact
Robin Pulkkinen, CFO, tel. +358 50 505 9932
robin.pulkkinen@revenio.fi

Distribution
Key media
www.reveniogroup.fi/en

Revenio Group in brief
Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, microperimeters, and perimeters as well as software solutions under the iCare brand.

In 2025, the Group’s net sales totaled EUR 109.7 million, with an operating profit of EUR 25.4 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.